

↑
December

=> d ibib abs hitstr 112 1-4

L12 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:730050 HCAPLUS

DOCUMENT NUMBER: 143:367274

TITLE: Design and Synthesis of Tricyclic Corticotropin-Releasing Factor-1 Antagonists

AUTHOR(S): Gross, Raymond S.; Guo, Zhiqiang; Dyck, Brian; Coon, Tim; **Huang, Charles Q.**; Lowe, Richard F.; Marinkovic, Dragan; Moorjani, Manisha; Nelson, Jodene; Zamani-Kord, Said; Grigoriadis, Dimitri E.; Hoare, Sam R. J.; Crowe, Paul D.; Bu, Jane Han; Haddach, Mustapha; McCarthy, James; Saunders, John; Sullivan, Robert; Chen, TaKung; Williams, John P.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Lead Discovery and Preclinical Development, Neurocrine Biosciences, San Diego, CA, 92130, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48(18), 5780-5793

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Antagonists of the corticotropin-releasing factor (**CRF**) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochem. properties, new tricyclic CRF1 antagonists were designed, synthesized, and tested for biol. activity. As a result of studies aimed at establishing a relationship between structure and CRF1 binding affinity, NBI 35965 [i.e., (7S)-6-(cyclopropylmethyl)-2-(2,4-dichlorophenyl)-7-ethyl-7,8-dihydro-4-methyl-6H-1,3,6,8a-tetraazaacenaphthylene (I)] was identified as a high-affinity antagonist with a pKi value of 8.5. I proved to be a functional CRF1 antagonist with pIC50 values of 7.1 and 6.9 in the in vitro **CRF**-stimulated cAMP accumulation and ACTH production assays, resp., and I also reduced **CRF** or stress induced ACTH production in vivo.


IT **141-97-9**, Ethyl acetoacetate

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1,3,6,8a-tetraazaacenaphthylene derivs. and study of their activity as corticotropin-releasing factor-1 antagonists)

RN 141-97-9 HCAPLUS

CN Butanoic acid, 3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT **195055-03-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1,3,6,8a-tetraazaacenaphthylene derivs. and study of their activity as corticotropin-releasing factor-1 antagonists)

RN 195055-03-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:629705 HCAPLUS

DOCUMENT NUMBER: 141:295971

TITLE: Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

AUTHOR(S): Chen, Chen; Wilcoxon, Keith M.; Huang, Charles Q.; Xie, Yun-Feng; McCarthy, James R.; Webb, Thomas R.; Zhu, Yun-Fei; Saunders, John; Liu, Xin-Jun; Chen, Ta-Kung; Bozigian, Haig; Grigoriadis, Dimitri E.
CORPORATE SOURCE: Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(19), 4787-4798

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:295971

GI



I

AB It has been shown that 3-phenylpyrazolo[1,5-a]pyrimidines were potent antagonists of the human corticotropin-releasing factor-1 receptor. A series of 3-pyridylpyrazolo[1,5-a]pyrimidines, e.g., I, containing a weakly basic pyridine ring at the 3-position of the bicyclic nucleus was designed to reduce lipophilicity from the initial lead compound. These

3-pyridyl compds. exhibited potent antagonists at the human CRF1 receptor. Moreover, the hydrophilic and weakly basic pyridine moiety increased the water solubility of some analogs. I exhibited good binding affinity at the human CRF1 receptor with a K_i value of 3.5 nM. As a functional antagonist, it dose-dependently inhibited CRF-stimulated cAMP production in cells expressing the CRF1 receptor (IC_{50} = 50 nM), and CRF-stimulated ACTH release from cultured rat pituitary cells (IC_{50} = 20 nM). I had a log P value of 4.9 and water solubility of greater than 10 mg/mL. Pharmacokinetic studies in rats showed that I was orally bioavailable and able to penetrate into the brain. I has been demonstrated in vivo efficacy in animal behavioral models that measure anxiolytic activity. These results suggest that analogs from this series were potent CRF1 receptor antagonists with proper physicochem. properties and good pharmacokinetic profiles. I was developed into a clin. compound and exhibited efficacy in patients with major depression.

IT 195055-07-3P 195055-09-5P


RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, corticotropin-releasing factor receptor activity, and structure-activity relationship of dimethyl(pyridinyl)

aminopyrazolopyrimidine derivs.)


RN 195055-07-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-(3-methyl-5-nitro-2-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 195055-09-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-amino-3-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



IT 195055-01-7P 195055-11-9P 195055-24-4P

195055-48-2P 195055-49-3P 195055-50-6P

195055-52-8P 195055-53-9P 195055-57-3P

195055-61-9P 195055-77-7P 195059-24-6P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, corticotropin-releasing factor receptor activity, and structure-activity relationship of dimethyl(pyridinyl)

aminopyrazolopyrimidine derivs.)


RN 195055-01-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-11-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[5-(dimethylamino)-3-methyl-2-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-24-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-48-2 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-49-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 195055-50-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-(phenylmethyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-52-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-dibutyl-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-53-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-57-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-2-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-61-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4,6-dimethyl-3-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-77-7 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-(6-methyl-3-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195059-24-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




IT **141-97-9**, Ethyl acetoacetate **26389-60-6**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation, corticotropin-releasing factor receptor activity, and structure-activity relationship of dimethyl(pyridinyl) aminopyrazolopyrimidine derivs.)
 RN 141-97-9 HCAPLUS
 CN Butanoic acid, 3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 26389-60-6 HCAPLUS
 CN Cyclopropanemethanamine, N-propyl- (9CI) (CA INDEX NAME)



IT **195055-65-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, corticotropin-releasing factor receptor activity, and structure-activity relationship of dimethyl(pyridinyl) aminopyrazolopyrimidine derivs.)
 RN 195055-65-3 HCAPLUS
 CN 2-Pyridinamine, 5-(7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




IT 195055-03-9P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, corticotropin-releasing factor receptor activity, pharmacokinetics, structure-activity relationship, and CNS activity of dimethyl(pyridinyl)aminopyrazolopyrimidine derivs.)

RN 195055-03-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




IT 195055-66-4P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, corticotropin-releasing factor receptor activity, pharmacokinetics, structure-activity relationship, and CNS activity of dimethyl(pyridinyl)aminopyrazolopyrimidine derivs.)

RN 195055-66-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:92404 HCAPLUS
 DOCUMENT NUMBER: 138:137328
 TITLE: Preparation of tricyclic compounds as CRF
 receptor antagonists
 INVENTOR(S): Haddach, Mustapha; Dyck, Brian P.; Huang, Charles
 Q.; Nelson, Jodie; Guo, Zhiqiang; McCarthy,
 James R.
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: U.S., 78 pp., Cont.-in-part of U.S. Ser. No. 401,364,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514982	B1	20030204	US 1999-439840	19991112
ES 2180338	T3	20030201	ES 1999-960363	19991112
PT 1129091	T	20030228	PT 1999-960363	19991112
US 6531475	B1	20030311	US 2000-574751	20000518
ZA 2001004441	A	20020530	ZA 2001-4441	20010530
US 2004087589	A1	20040506	US 2003-339780	20030108
US 2004157851	A1	20040812	US 2003-701394	20031104
PRIORITY APPLN. INFO.:			US 1998-191073	B2 19981112
			US 1999-370837	B2 19990809
			US 1999-401364	B2 19990921
			US 1999-439840	A2 19991112
			US 2000-574751	A1 20000518
			US 2003-339780	B1 20030108
OTHER SOURCE(S):	MARPAT 138:137328			
GI				



AB The title compds. [I; n = 1-2; A, C = N, C, CH; B = N, CR₃; with the provisos that at least one of A, B and C = N; A, B and C are not all N; and either A-B or B-C is a double bond; X = N, CH; Ar = (un)substituted

aryl, heteroaryl; R = alkyl, alkylidenyl, arylalkyl, heteroarylalkyl; m = 0-3; R1 = C(H)O, 1R4R5, SO2R5; R2 = H, alkyl; R3 = H, alkyl, haloalkyl; R4 = H, alkyl, halo, etc.; R5 = -YZR6; (un)substituted alkanediyl, a direct bond; Z = NH, O, S, etc.; R6 = H, alkyl, aryl, etc.] which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of **CRF** in a warm-blooded animals, such as stroke, depression, and anxiety, were prepared E.g., a multi-step synthesis of II which showed Ki of < 250 nM against **CRF** receptor binding, was given.

IT 141-97-9, Butanoic acid, 3-oxo-, ethyl ester
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of tricyclic compds. as **CRF** receptor antagonists)
 RN 141-97-9 HCAPLUS
 CN Butanoic acid, 3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:542450 HCAPLUS

DOCUMENT NUMBER: 127:220669

TITLE: **Pyrazolopyrimidines as CRF**
 receptor antagonists

INVENTOR(S): **Chen, Chen; Webb, Thomas R.;**
McCarthy, James R.; Moran, Terence J.
; Wilcoxon, Keith M.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.; Neurocrine
 Biosciences, Inc.

SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729109	A1	19970814	WO 1997-EP459	19970130
W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2233285	AA	19970814	CA 1997-2233285	19970130
AU 9715991	A1	19970828	AU 1997-15991	19970130
AU 713673	B2	19991209		
EP 880523	A1	19981202	EP 1997-902295	19970130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1205009	A	19990113	CN 1997-191382	19970130
CN 1090189	B	20020904		
BR 9707391	A	19990720	BR 1997-7391	19970130

NZ 330119	A	20000228	NZ 1997-330119	19970130
JP 2000503661	T2	20000328	JP 1997-528123	19970130
JP 3356291	B2	20021216		
JP 2002121194	A2	20020423	JP 2001-265611	19970130
EE 4282	B1	20040415	EE 1998-124	19970130
TW 449599	B	20010811	TW 1997-86101373	19970205
ZA 9700989	A	19980806	ZA 1997-989	19970206
NO 9801357	A	19980803	NO 1998-1357	19980325
NO 310292	B1	20010618		
US 2003125341	A1	20030703	US 1999-117717	19990302
US 6664261	B2	20031216		
US 2004127483	A1	20040701	US 2003-665740	20030919
PRIORITY APPLN. INFO.:			US 1996-11279P	P 19960207
			US 1996-27688P	P 19961008
			JP 1997-528123	A3 19970130
			WO 1997-EP459	W 19970130
			US 1999-117717	A1 19990302
OTHER SOURCE(S):	MARPAT 127:220669			
GI				



AB Title compds. I [R = (un)substituted Ph, pyridyl; R¹ = substituted NH₂, (un)substituted alkoxy; R² = alkyl, alkoxy, alkylthio; R³ = H, alkyl, alkylsulfonyl, alkylsulfoxy, alkylthio] having **CRF** receptor antagonistic properties, were prepared Thus, I [R = 2,4-Cl₂C₆H₃, R¹ = N-propyl-N-cyclopropylmethylamino, R² = Me, R³ = H, II] was obtained by treating 3-amino-4-(2,4-dichlorophenyl)pyrazole with MeCOCH₂CO₂Et, chlorinating I [R = 2,4-Cl₂C₆H₃, R¹ = OH, R² = Me, R³ = H] and aminating I [R¹ = Cl]. II had a K_i for **CRF** receptor inhibition of <250 nM.


IT 16142-51-1P 104906-17-4P 195054-42-3P
 195054-43-4P 195054-44-5P 195054-45-6P
 195054-46-7P 195054-47-8P 195054-48-9P
 195054-49-0P 195054-50-3P 195054-51-4P
 195054-52-5P 195054-53-6P 195054-54-7P
 195054-55-8P 195054-56-9P 195054-57-0P
 195054-58-1P 195054-59-2P 195054-60-5P
 195054-61-6P 195054-62-7P 195054-63-8P
 195054-64-9P 195054-65-0P 195054-66-1P
 195054-67-2P 195054-68-3P 195054-69-4P
 195054-70-7P 195054-71-8P 195054-72-9P
 195054-73-0P 195054-74-1P 195054-75-2P
 195054-76-3P 195054-77-4P 195054-78-5P
 195054-79-6P 195054-80-9P 195054-81-0P
 195054-82-1P 195054-83-2P 195054-84-3P
 195054-86-5P 195054-88-7P 195054-90-1P
 195054-92-3P 195054-94-5P 195054-96-7P
 195054-97-8P 195054-99-0P 195055-01-7P
 195055-03-9P 195055-05-1P 195055-07-3P
 195055-09-5P 195055-11-9P 195055-13-1P

195055-15-3P 195055-18-6P 195055-21-1P
 195055-24-4P 195055-27-7P 195055-29-9P
 195055-31-3P 195055-33-5P 195055-34-6P
 195055-35-7P 195055-36-8P 195055-37-9P
 195055-38-0P 195055-39-1P 195055-40-4P
 195055-41-5P 195055-42-6P 195055-43-7P
 195055-44-8P 195055-45-9P 195055-46-0P
 195055-47-1P 195055-48-2P 195055-49-3P
 195055-50-6P 195055-51-7P 195055-52-8P
 195055-53-9P 195055-54-0P 195055-55-1P
 195055-56-2P 195055-57-3P 195055-58-4P
 195055-59-5P 195055-60-8P 195055-61-9P
 195055-66-4P 195055-68-6P 195055-69-7P
 195055-70-0P 195055-71-1P 195055-72-2P
 195055-73-3P 195055-74-4P 195055-75-5P
 195055-76-6P 195055-77-7P 195055-78-8P
 195055-79-9P 195055-80-2P 195055-81-3P
 195055-82-4P 195055-83-5P 195055-84-6P
 195055-85-7P 195055-86-8P 195055-87-9P
 195055-88-0P 195055-89-1P 195055-90-4P
 195055-91-5P 195055-92-6P 195055-93-7P
 195055-94-8P 195055-95-9P 195055-96-0P
 195055-97-1P 195055-98-2P 195055-99-3P
 195056-00-9P 195056-01-0P 195059-24-6P
 195059-25-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of **aminopyrazolopyrimidines** as **CRF** receptor antagonists)


RN 16142-51-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,2,5-trimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 104906-17-4 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 5-methyl-3-phenyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 195054-42-3 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-propyl-

(9CI) (CA INDEX NAME)




RN 195054-43-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 195054-44-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,1-dimethylethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-45-6 HCAPLUS

CN 1-Propanol, 3-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195054-46-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-47-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-48-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 195054-49-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-50-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195054-51-4 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1,3-dimethylbutyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195054-52-5 HCAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195054-53-6 HCAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195054-54-7 HCAPLUS


CN 1-Butanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195054-55-8 HCAPLUS

Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195054-56-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-57-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195054-58-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-59-2 HCAPLUS

CN Ethanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (9CI) (CA INDEX NAME)




RN 195054-60-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-61-6 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chlorophenyl)-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195054-62-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-(2,6-dichlorophenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 195054-63-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,6-dichlorophenyl)-N-(2-methoxyethyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-64-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-65-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 195054-66-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-(2,4-dichlorophenyl)-N-(1,2-dimethylpropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195054-67-2 HCAPLUS

CN Ethanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 195054-68-3 HCAPLUS

CN Ethanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 195054-69-4 HCAPLUS

CN Ethanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 195054-70-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 195054-71-8 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-72-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-methylethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-73-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(1-ethylpentyl)-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-74-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(diethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195054-75-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-[(3-methoxyphenyl)methyl]-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-76-3 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N,N,5-trimethyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-77-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N,N-diethyl-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 195054-78-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195054-79-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-80-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N,N-bis(1-methylethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-81-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-82-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-83-2 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)-N,N-di-2-propenyl- (9CI) (CA INDEX NAME)



RN 195054-84-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-2-(methylsulfinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-86-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-2-(methylsulfonyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-88-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(3-

methoxypropyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-90-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-butyl-3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 195054-92-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-butyl-3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-94-5 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chlorophenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195054-96-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195054-97-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-(2,4-dichlorophenyl)-7-ethoxy-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 195054-99-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-01-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-03-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-05-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-chloro-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 195055-07-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-(3-methyl-5-nitro-2-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-09-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-amino-3-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-11-9 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[5-(dimethylamino)-3-methyl-2-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-13-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N,N-bis(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195055-15-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxy-1-methylethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 195055-18-6 HCAPLUS

CN 1-Hexanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-21-1 HCAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-24-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-27-7 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 195055-29-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-31-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-5-methyl-3-(6-methyl-3-pyridinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-33-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-dibutyl-5-methyl-3-(6-methyl-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 195055-34-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dimethoxyphenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-35-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-methyl-N,N-dipropyl-3-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195055-36-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-5-methyl-N-propyl-3-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195055-37-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-5-methyl-N-propyl-3-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 195055-38-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-N-ethyl-5-methyl-3-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195055-39-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl-3-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195055-40-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-2-ethyl-5-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-41-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chlorophenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-42-6 HCAPLUS

CN Ethanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 195055-43-7 HCAPLUS

CN 1-Hexanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-44-8 HCAPLUS

CN 1-Pentanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 195055-45-9 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chlorophenyl)-2,5-dimethyl-N-[2-(methylthio)ethyl]- (9CI) (CA INDEX NAME)



RN 195055-46-0 HCAPLUS


CN 1-Pentanol, 2-[[3-(4-chlorophenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-4-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195055-47-1 HCAPLUS

CN 1-Hexanol, 2-[[3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 195055-48-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-49-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-50-6 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-(phenylmethyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-51-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-di-2-propenyl- (9CI) (CA INDEX NAME)




RN 195055-52-8 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-dibutyl-3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-53-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1-ethylpropyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 195055-54-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 195055-55-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-N-(1,3-dimethylbutyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-56-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-[6-(dimethylamino)-4-methyl-3-

pyridinyl]-N,2,5-trimethyl- (9CI) (CA INDEX NAME)




RN 195055-57-3 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-2-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-58-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[6-(dimethylamino)-2-methyl-3-pyridinyl]-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-59-5 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-[6-(dimethylamino)-2-methyl-3-pyridinyl]-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-60-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-dibutyl-3-[6-(dimethylamino)-2-methyl-3-pyridinyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 195055-61-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4,6-dimethyl-3-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-66-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 195055-68-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-chloro-3-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-69-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-fluoro-3-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-70-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[5-(diethylamino)-3-methyl-2-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-71-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(1-piperidinyl)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-72-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-(5-methyl-3-nitro-2-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-73-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-amino-5-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-74-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-chloro-5-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-75-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[5-methyl-3-(methyldipropylamino)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-76-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[3-(dimethylamino)-5-methyl-2-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-77-7 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-(6-methyl-3-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-78-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-2,5-dimethyl-3-[4-(1-methylethyl)phenyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-79-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 195055-80-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-81-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-(2,4-dimethoxyphenyl)-5-methyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-82-4 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-83-5 HCAPLUS

CN Ethanol, 2-[[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (9CI) (CA INDEX NAME)




RN 195055-84-6 HCAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 2,5-dimethyl-3-[3-methyl-5-(methylamino)-2-pyridinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-85-7 HCAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-86-8 HCAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dimethoxyphenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-87-9 HCAPLUS
CN 2-Propanol, 1-[[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino]- (9CI) (CA INDEX NAME)




RN 195055-88-0 HCAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 195055-89-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-90-4 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(3-methoxyphenyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-91-5 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-(4-chlorophenyl)-7-[2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 195055-92-6 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-(4-chlorophenyl)-7-(2-ethyl-1-piperidinyl)-
 2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-93-7 HCAPLUS
 CN 2-Pyridinamine, 5-[7-(2-ethyl-1-piperidinyl)-2,5-dimethylpyrazolo[1,5-
 a]pyrimidin-3-yl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




RN 195055-94-8 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(4,6-dimethyl-3-
 pyridinyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195055-95-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-iodo-3-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-96-0 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195055-97-1 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-98-2 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,5-dichloro-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 195055-99-3 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,5-dichloro-2-pyridinyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195056-00-9 HCAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(3,5-dichloro-2-pyridinyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 195056-01-0 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(5-methoxy-3-methyl-2-pyridinyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195059-24-6 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 195059-25-7 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




IT 141-97-9, Ethyl acetoacetate 7533-40-6, (S)-Leucinol
 26389-60-6 53448-09-2 195055-62-0
 195055-65-3 195055-67-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of **aminopyrazolopyrimidines** as **CRF** receptor
 antagonists)
 RN 141-97-9 HCAPLUS
 CN Butanoic acid, 3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 7533-40-6 HCAPLUS
 CN 1-Pentanol, 2-amino-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 26389-60-6 HCAPLUS
 CN Cyclopropanemethanamine, N-propyl- (9CI) (CA INDEX NAME)




RN 53448-09-2 HCAPLUS
 CN 1-Pentanol, 2-amino-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 195055-62-0 HCAPLUS

CN 1H-Pyrazol-3-amine, 4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 195055-65-3 HCAPLUS

CN 2-Pyridinamine, 5-(7-chloro-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N,4-trimethyl- (9CI) (CA INDEX NAME)



RN 195055-67-5 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




IT 195055-63-1P 195055-64-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

RN 195055-63-1 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 195055-64-2 HCAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

